Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
national blog main
national top stories
24
×
seattle blog main
24
×
startups
24
×
boston blog main
detroit blog main
san francisco blog main
new york blog main
raleigh-durham blog main
san diego blog main
texas blog main
wisconsin blog main
boston top stories
detroit top stories
life sciences
texas top stories
boulder/denver blog main
indiana blog main
national
new york top stories
raleigh-durham top stories
san diego top stories
san francisco top stories
seattle top stories
wisconsin top stories
biotech
boulder/denver top stories
indiana top stories
deals
cancer
fda
cancer immunotherapy
clinical trials
alzheimer's disease
eli lilly
investing
novartis
pfizer
merck
abbvie
What
roundup
bio
drug
companies
cancer
ceo
life
acquisitions
alzheimer’s
biotech
develop
drugs
fda
nash
new
news
pfizer’s
pharmaceutical
science
sciences
week
ahead
amid
annual
asco
attention
biggest
black
bombast
buy
capital
cash
caught
city
company
continue
control
coronavirus
covid
crispr
Language
unset
unknown
Current search:
startups
×
" seattle blog main "
×
" national top stories "
×
@xconomy.com
3 years ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com
3 years ago
Bio Roundup: MESO’s Miss, Pfizer’s Cancer Bet, Vaccine Promise & More
@xconomy.com
3 years ago
Bio Roundup: MESO’s Miss, Pfizer’s Cancer Bet, Vaccine Promise & More
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More
@xconomy.com
4 years ago
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More
@xconomy.com
4 years ago
Five Years After Y Combinator First Admits Biotechs, They’re Dug In
@xconomy.com
4 years ago
Biotech Roundup: Vaping Toll Rises, NASH News, Akcea Shakeup & More
@xconomy.com
4 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
4 years ago
Review: Inside the House of Lies at Theranos
@xconomy.com
5 years ago
HAP Partners With Livongo on Tech-Enabled Diabetes Compliance Program
@xconomy.com
5 years ago
Bio Roundup: Generic Drugs Graft, ASCO Ahead, ElevateBio Rises & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More
@xconomy.com
5 years ago
Bio Roundup: #JPM19 Notes, Loxo Buyout, Black Diamond’s Cash & More
@xconomy.com
5 years ago
From Immigration to Taxes, Execs Talk Trump Effect on Innovation
@xconomy.com
5 years ago
Bio Roundup: Midterm Fallout, Alzheimer’s Search, Postpartum Panel
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More
@xconomy.com
5 years ago
Circulation CEO Talks Sale to LogistiCare & Amazon’s Healthcare Play
@xconomy.com
5 years ago
In Boston’s Shadow, Rhode Island Fights for Life Science Jobs, Respect
@xconomy.com
6 years ago
Biotech Roundup: ASCO Ahead, CAMP4’s Cash, Ambien Tweeting & More